Lead Product(s) : Nelfinavir
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Nelfinavir in Systemic Lupus Erythematosus
Details : Nelfinavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lupus Erythematosus, Systemic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2014
Lead Product(s) : Nelfinavir
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : National Institute of Arthritis and Musculoskeletal and Skin Diseases
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
